16,128 Shares in Abbott Laboratories $ABT Bought by Bank OZK

Key Points

• Bank OZK purchased 16,128 Abbott Laboratories shares worth approximately $1.46 million in the second quarter. Institutional investors and hedge funds collectively own 75.18% of Abbott’s outstanding stock.
• Abbott reported quarterly earnings of $1.31 per share, surpassing estimates, while revenue rose 13% year over year to $12.59 billion. The company issued third-quarter EPS guidance of $1.38–$1.46 and maintained full-year 2026 guidance of $5.45–$5.60.
• Analysts remain broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $119.50. Abbott also pays a quarterly dividend of $0.63 per share, equivalent to a 2.3% annualized yield.

Bank OZK purchased a new stake in Abbott Laboratories (NYSE:ABT - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 16,128 shares of the healthcare product maker's stock, valued at approximately $1,463,000.

Several other institutional investors have also added to or reduced their stakes in the business. Freemont Management S.A. raised its stake in Abbott Laboratories by 197.2% in the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker's stock valued at $1,341,000 after purchasing an additional 7,100 shares during the last quarter. Thrivent Financial for Lutherans raised its position in shares of Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker's stock valued at $30,931,000 after buying an additional 48,286 shares during the last quarter. Aureus Asset Management LLC lifted its stake in shares of Abbott Laboratories by 25.0% in the first quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker's stock worth $34,078,000 after buying an additional 66,422 shares in the last quarter. North Dakota State Investment Board purchased a new stake in Abbott Laboratories during the 4th quarter valued at about $7,439,000. Finally, Thompson Investment Management Inc. lifted its stake in Abbott Laboratories by 786.0% in the 2nd quarter. Thompson Investment Management Inc. now owns 14,061 shares of the healthcare product maker's stock worth $1,276,000 after purchasing an additional 12,474 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott outperformed the market during the latest trading session, supported by continued investor interest in the diversified healthcare-products maker. Its shares are trading above both the 50-day and 200-day moving averages, indicating favorable near-term momentum. Abbott Exceeds Market Returns: Some Facts to Consider
• Positive Sentiment: Abbott’s latest reported quarter showed solid fundamentals: adjusted earnings exceeded consensus estimates, revenue surpassed expectations, and sales increased 13% year over year. Management’s 2026 earnings guidance remains consistent with analyst expectations, helping support the investment case.
• Neutral Sentiment: Industry research projects continued growth in cardiovascular ultrasound systems through 2030, driven by portable devices, artificial intelligence, 3D/Doppler imaging and remote diagnostics. The opportunity is broadly relevant to Abbott’s cardiovascular-device business, although the report primarily highlights GE HealthCare, Philips and Siemens Healthineers rather than announcing a specific Abbott development. Cardiovascular Ultrasound Systems Market Outlook
• Neutral Sentiment: Recent commentary notes that Abbott has lagged the healthcare sector over the past year, but analysts remain broadly optimistic about its long-term prospects. This creates a mixed backdrop: valuation and relative performance could restrain gains, while analyst confidence and business diversification provide support. Abbott Laboratories Stock: Is ABT Underperforming the Healthcare Sector?

Analysts Set New Price Targets

Several research firms recently commented on ABT. BTIG Research increased their price target on Abbott Laboratories from $131.00 to $134.00 and gave the company a "buy" rating in a report on Friday, July 17th. Wells Fargo & Company boosted their price target on shares of Abbott Laboratories from $109.00 to $112.00 and gave the company an "overweight" rating in a research report on Friday, July 17th. The Goldman Sachs Group cut their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating for the company in a research report on Wednesday, May 27th. Robert W. Baird began coverage on shares of Abbott Laboratories in a research note on Wednesday, July 1st. They issued an "outperform" rating and a $121.00 price target for the company. Finally, Citigroup lifted their price target on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a "buy" rating in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $119.50.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $110.52 on Thursday. The company's 50 day simple moving average is $103.83 and its 200-day simple moving average is $100.09. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The company has a market capitalization of $191.24 billion, a price-to-earnings ratio of 35.77, a price-to-earnings-growth ratio of 2.02 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter last year, the firm earned $1.26 EPS. The firm's revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were paid a dividend of $0.63 per share. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories's dividend payout ratio is 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source